 This multi-center trial will be conducted in Argentina, Australia, China, Colombia, Hong Kong, Mexico, Republic of Korea, Russia, Saudi Arabia, Singapore, South Africa, Taiwan, and Turkey. The data for Group 1 and Group 2 participants will be collected from date of cHL or RRHL diagnosis until the death of participant or the date of data collection, whichever occurs first. The overall time for data collection in the study will be approximately 12 months. 